Enzyme replacement therapy on hypophosphatasia mouse model
Hypophosphatasia (HPP) is an inborn error of metabolism caused by deficiency of the tissue-nonspecific alkaline phosphatase (TNSALP), resulting in a defect of bone mineralization. Natural substrates for this ectoenzyme accumulate extracellulary including inorganic pyrophosphate (PPi), an inhibitor of mineralization, and pyridoxal 5-phosphate (PLP), a co-factor form of vitamin B6. Enzyme replacement therapy (ERT) for HPP by functional TNSALP is one of the therapeutic options. The C-terminal-anchorless human recombinant TNSALP derived from Chinese hamster ovary cell lines was purified. TNSALP-null mice (Akp2 -/- ), an infantile model of HPP, were treated from birth using TNSALP and vitamin B6 diet. Long-term efficacy studies of ERT consisted of every 3 days subcutaneous or intravenous injections till 28 days old (dose 20 U/g) and subsequently every 3 days intravenous injections for 6 months (dose 10 U/g). We assessed therapeutic effect by growth and survival rates, fertility, skeletal manifestations, and radiographic and pathological finding. Treated Akp2 -/- mice grew normally till 4 weeks and appeared well with a minimum skeletal abnormality as well as absence of epilepsy, compared with untreated mice which died by 3 weeks old. The prognosis of TNSALP-treated Akp2 -/- mice was improved substantially: 1) prolonged life span over 6 months, 2) improvement of the growth, and 3) normal fertility. After 6 months of treatment, we found moderate hypomineralization with abnormal proliferative chondrocytes in growth plate and articular cartilage. In conclusion, ERT with human native TNSALP improves substantial clinical manifestations in Akp2 -/- mice, suggesting that ERT with anchorless TNSALP is also a potential therapy for HPP.
KeywordsBone Mineral Density Enzyme Replacement Therapy Fabry Disease Homozygous Mouse Hypophosphatasia
areas under the curve
bone mineral density
a deca-aspartate sequence
enzyme replacement therapy
hematoxylin and eosin
lysosomal storage disorders
mean residence time
apparent elimination half-life
concentration peak time
tissue-nonspecific alkaline phosphatase
steady-state distribution volume
This work was supported by grants from the Austrian MPS Society, and International Morquio Organization (Carol Ann Foundation). S.T. is supported by National Institutes of Health grant 8P20 GM103464-08. The content of the article has not been influenced by the sponsors.
Dr. Tomatsu, a principal investigator, was the former employee of Saint Louis University, while the experiments of the project were conducted and completed.
Conflict of interest
- Baumgartner-Sigl S, Haberlandt E, Mumm S et al (2007) Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissuenonspecific alkaline phosphatase gene. Bone 40:1655–61PubMedCrossRefGoogle Scholar
- MacGregor GR, Zambrowicz BP, Soriano P (1995) Tissue non-specific alkaline phosphatase is expressed in both embryonic and extraembryonic lineages during mouse embryogenesis but is not requires for migration of primordial germ cells. Development 121(5):1487–96Google Scholar
- Whyte MP (2001) Hypophosphatasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW (eds) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, pp 5313–29Google Scholar
- Whyte MP, Mahuren JD, Fedde KN, Cole FS, McCabe ER, Coburn SP (1988) Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5'-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest 81:1234–9PubMedCentralPubMedCrossRefGoogle Scholar